Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
KT095
i
Other names:
KT095
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Nanjing KATI
Drug class:
B7-H3-targeted CAR-T immunotherapy
Related drugs:
‹
s (1)
4SCAR-276 (0)
B7-H3 CAR-T (0)
BP102 (0)
CAR.B7-H3 T (0)
CD276 CAR-T (0)
GD2, PSMA and CD276 CAR-T (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
MT027 (0)
QH104 (0)
SC-CAR4BRAIN (0)
s (0)
TAA6-CAR-T (0)
UTAA06 (0)
Undisclosed EGFR/B7H3 CAR-T (0)
fhB7H3.CAR-Ts (0)
s (1)
4SCAR-276 (0)
B7-H3 CAR-T (0)
BP102 (0)
CAR.B7-H3 T (0)
CD276 CAR-T (0)
GD2, PSMA and CD276 CAR-T (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
MT027 (0)
QH104 (0)
SC-CAR4BRAIN (0)
s (0)
TAA6-CAR-T (0)
UTAA06 (0)
Undisclosed EGFR/B7H3 CAR-T (0)
fhB7H3.CAR-Ts (0)
›
Associations
News
Trials
Filter by
Latest
over2years
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors (clinicaltrials.gov)
P1, N=30, Not yet recruiting, The First People's Hospital of Lianyungang
over 2 years ago
New P1 trial • CAR T-Cell Therapy
|
CD276 (CD276 Molecule)
|
cyclophosphamide • fludarabine IV • KT095
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login